PLK1 抗体 (AA 201-300)
(1 reference)Quick Overview for PLK1 抗体 (AA 201-300) (ABIN700435)
抗原
See all PLK1 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 201-300
-
交叉反应
- 人
-
预测反应
- Mouse,Rat,Dog,Pig,Rabbit
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from human PLK1
-
亚型
- IgG
-
-
anti-Polo-Like Kinase 1 (PLK1) (AA 331-508) antibody
PLK1 适用: 人, 小鼠 WB, ELISA, IHC, FACS 宿主: 小鼠 Monoclonal 3C11 unconjugated
anti-Polo-Like Kinase 1 (PLK1) (AA 1-603) antibodyPLK1 适用: 人 WB, ELISA, IF 宿主: 小鼠 Monoclonal 4G11 unconjugated
anti-Polo-Like Kinase 1 (PLK1) (AA 1-603) antibodyPLK1 适用: 人 WB, ELISA, IF, IP, PLA 宿主: 小鼠 Monoclonal 2G12 unconjugated
anti-Polo-Like Kinase 1 (PLK1) antibodyPLK1 适用: 人 WB, IHC, IP, IHC (p), FACS 宿主: 小鼠 Monoclonal 5C1 unconjugated
anti-Polo-Like Kinase 1 (PLK1) antibodyPLK1 适用: 人, 犬 WB, IHC, IP, IHC (p) 宿主: 小鼠 Monoclonal 6C6 unconjugated
anti-Polo-Like Kinase 1 (PLK1) antibodyPLK1 适用: 人 WB, IHC, IP, IHC (p) 宿主: 小鼠 Monoclonal 1D4 unconjugated
anti-Polo-Like Kinase 1 (PLK1) antibodyPLK1 适用: 人, 犬, 猴 WB, IF, IP, FACS 宿主: 小鼠 Monoclonal 8C12 unconjugated
anti-Polo-Like Kinase 1 (PLK1) antibodyPLK1 适用: 人 WB, IHC, IP, IHC (p), FACS 宿主: 小鼠 Monoclonal 3F12 unconjugated
anti-Polo-Like Kinase 1 (PLK1) (AA 331-508) antibodyPLK1 适用: 人 ELISA, ICC 宿主: 小鼠 Monoclonal 1D1 unconjugated
anti-Polo-Like Kinase 1 (PLK1) (AA 331-508) antibodyPLK1 适用: 人 WB, ELISA, IF/ICC 宿主: 小鼠 Monoclonal unconjugated
-
-
应用备注
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500 -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
有效期
- 12 months
-
-
-
: "Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer." in: Nature communications, Vol. 9, Issue 1, pp. 16, (2018) (PubMed).
-
: "Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer." in: Nature communications, Vol. 9, Issue 1, pp. 16, (2018) (PubMed).
-
- PLK1 (Polo-Like Kinase 1 (PLK1))
-
别名
- PLK1
-
背景
-
Synonyms: PLK, STPK13, Serine/threonine-protein kinase PLK1, Polo-like kinase 1, PLK-1, Serine/threonine-protein kinase 13, PLK1
Background: PLK1 (polo-like kinase 1) is a member of the serine/threonine protein kinase family, cdc5/polo subfamily. PLK1 contains two polo box domains with a predicted molecular weight of 68 kDa. PLK1 has been shown to regulate cdc2/cyclin B through phosphorylation and activation of cdc25c phosphatase. PLK1 is modified by phosphorylation at Threonine 210. PLK1 may also be required for cell division. Depletion of PLK1 results in apoptosis and deregulation of expression of PKL1 is correlated with development of many malignancies.
-
基因ID
- 5347
-
UniProt
- P53350
-
途径
- Cell Division Cycle, M Phase
抗原
-
